The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Gamifant
emapalumab-lzsg · EMAPALUMAB 10 mg/2mL · Injection · Intravenous · Swedish Orphan Biovitrum AB (publ)
NDC 66658-0501-01 · 1 VIAL, SINGLE-USE in 1 CARTON / 2 mL in 1 VIAL, SINGLE-USE · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$3,711.00
Reported to Texas DSHS · 2026 annual filing · Sobi Inc
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 1 MG
$392.780
HCPCS J9210 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$94,377
14 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761107
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of emapalumab-lzsg (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Swedish Orphan Biovitrum AB (publ) | EMAPALUMAB 10 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Swedish Orphan Biovitrum AB (publ) | EMAPALUMAB 100 mg/20mL | Jul 15, 2026 | Sep 2, 2026 |
| Swedish Orphan Biovitrum AB (publ) | EMAPALUMAB 100 mg/4mL | Jul 15, 2026 | Sep 2, 2026 |
| Swedish Orphan Biovitrum AB (publ) | EMAPALUMAB 250 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Swedish Orphan Biovitrum AB (publ) | EMAPALUMAB 50 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Swedish Orphan Biovitrum AB (publ) | EMAPALUMAB 50 mg/2mL | Jul 15, 2026 | Sep 2, 2026 |
| Swedish Orphan Biovitrum AB (publ) | EMAPALUMAB 500 mg/20mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Gamifant — NDC 66658-0501-01," retrieved September 3, 2026, https://drugdashboards.com/drug/66658050101.
Free to cite with attribution — see how the data is put together.